Kugereranya kugurisha kwa Dulaglutide, Liraglutide na Semaglutide.

Igihangange mu bya farumasi Lilly, isosiyete y'Abanyamerika, na Novo Nordisk, isosiyete yo muri Danemarike, bakomeje gutangaza amakuru yo kugurisha ibicuruzwa byabo by’ibanze mu 2020: Dulaglutide yahindutse imiti ya TOP1 GLP-1, igurishwa $ 5.07Bn muri 2020, umwaka- kwiyongera ku mwaka kwiyongera 22.8%;liraglutide Gutangira kwinjira mugihe cyo kumanuka, kugurisha muri 2020 byagabanutse biva kuri $ 4.14Bn bigera kuri $ 3.93Bn, umwaka ushize wagabanutse 5.1%;semaglutide yazamutse cyane, aho igurisha ryageze kuri $ 3.72Bn muri 2020, umwaka ushize wiyongereyeho 119.9%.

Dulaglutide ya Lilly (izina ry'ubucuruzi Trulicity®) yatangijwe mu 2014 ihinduka ibiyobyabwenge bikwirakwizwa n’amadolari 5.07Bn mu myaka 6 gusa, ibaye nyampinga w’ibiyobyabwenge bya GLP-1.Igicuruzwa kimwe cya Novo Nordisk cyasubiye inyuma by'agateganyo inyuma ya Lilly.Liraglutide yayo (izina ry'ubucuruzi Victoza® na Saxenda®), yatangijwe mu 2009, yigeze kuba nyampinga wo kugurisha ibiyobyabwenge bya GLP-1, kandi igurishwa ryayo muri 2017 ryageze kuri $ 4.37Bn, nubwo hari ibimenyetso bibiri byerekana diyabete yo mu bwoko bwa II n'umubyibuho ukabije , imibare yo muri 2020 yerekana ko isoko ryibi biyobyabwenge ryinjiye mugihe cyo kugabanuka.Semaglutide imwe ya Novo Nordisk (amazina yubucuruzi Ozempic® na Rybelsus®) yakuze vuba kandi ikura mubindi biyobyabwenge bigurishwa $ 3.72Bn mumyaka itatu.Umuti ufite uburyo bubiri bwo gutera inshinge no gutegura umunwa.

Dufatiye ku miterere y'akarere, Leta zunze ubumwe z'Amerika nicyo gihugu nyamukuru kigurisha liraglutide, kikaba kigera kuri 60% muri 2020, umwaka ushize ugabanuka 11.02%;n’ubukungu bwifashe nabi muri Amerika ni bwo bwatumye igabanuka ry’isoko mpuzamahanga rya liraglutide.Agace ka EMEA (Uburayi, Uburasirazuba bwo hagati, Afurika) kateye imbere gahoro gahoro, hamwe na CAGR ya 1,6% gusa mumyaka itanu ishize;Ubushinwa nisoko ryihuta cyane, aho ryagurishijwe $ 182.50Mn muri 2020, hamwe n’ubwiyongere bw’umwaka buri mwaka bwa 42.39%.Kuva semaglutide iba ku isoko vuba, amasoko yose ari murwego rwo kuzamuka byihuse.Amerika iracyari isoko rinini, bingana na 80.04% by’igurisha muri 2020, umwaka ushize wiyongereyeho 106.08%;EMEA ifite umugabane wa 13,64% gusa ariko umwaka-mwaka wubwiyongere bwa 249.65%.Semaglutide yatangijwe mu Bushinwa mu 2020 igurishwa $ 1.61Mn.Igishushanyo cya 3 cyerekana uko akarere gahagaze dulaglutide.Nka soko rinini, Amerika ifite ibicuruzwa bigera kuri $ 3.836Bn, bingana na 75.69%, hamwe n’ubwiyongere buri mwaka bwa 79.18%.

Ipatanti yibanze ya liraglutide (Victoza® na Saxenda®) yarangirije mu Bushinwa kandi igiye kurangira muri Amerika, Ubuyapani n'Ubudage.Urugamba rwa Teva na Novo Nordisk rwarakemutse, kandi verisiyo rusange ya Teva izaboneka mu 2023. Mylan kandi yatanze icyifuzo cya ANDA muri FDA kuri liraglutide hamwe na PIV.Mugihe kirangiye gahoro gahoro patenti yibanze hamwe niterabwoba ryabakora ibiyobyabwenge rusange, ibiyobyabwenge bizinjira buhoro buhoro mugihe cyo kugabanuka.Ipatanti y’Amerika yo muri Trulicity® ntizarangira kugeza mu 2027, mu gihe patenti y’ibihugu by’ibihugu by’Uburayi n’Ubuyapani bitazarangira kugeza mu 2029, kandi kurinda ipatanti ni ndende kuruta iya liraglutide.Ipatanti yibanze ya semaglutide (Ozempic® na Rybelsus®) izarangira mu 2032 mugihe cyanyuma, kandi haracyari umwanya munini wo kuzamuka kw isoko, ariko igihe cyayo kirangirira mubushinwa ni 2026.